CRO Stock Overview
Operates as a pharmaceutical service and contract research company in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
hVIVO plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.23 |
| 52 Week High | UK£0.37 |
| 52 Week Low | UK£0.21 |
| Beta | 1.05 |
| 1 Month Change | -8.06% |
| 3 Month Change | -28.30% |
| 1 Year Change | -20.83% |
| 3 Year Change | -6.56% |
| 5 Year Change | 356.00% |
| Change since IPO | 273.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| CRO | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 4.6% | 0.2% | 0.7% |
| 1Y | -20.8% | -2.4% | 8.4% |
Return vs Industry: CRO underperformed the German Life Sciences industry which returned -3.6% over the past year.
Return vs Market: CRO underperformed the German Market which returned 8.4% over the past year.
Price Volatility
| CRO volatility | |
|---|---|
| CRO Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CRO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CRO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 274 | Mo Khan | www.hvivo.com |
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom. The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services. It provides services to big pharma and biotech organizations.
hVIVO plc Fundamentals Summary
| CRO fundamental statistics | |
|---|---|
| Market cap | €156.74m |
| Earnings (TTM) | €21.04m |
| Revenue (TTM) | €81.07m |
7.4x
P/E Ratio1.9x
P/S RatioIs CRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRO income statement (TTM) | |
|---|---|
| Revenue | UK£67.21m |
| Cost of Revenue | UK£50.65m |
| Gross Profit | UK£16.56m |
| Other Expenses | -UK£884.00k |
| Earnings | UK£17.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.026 |
| Gross Margin | 24.64% |
| Net Profit Margin | 25.96% |
| Debt/Equity Ratio | 0% |
How did CRO perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield8%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 13:43 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
hVIVO plc is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Simms | Arden Partners Plc. |
| Andrew Murray Darley | Cavendish |
| Stuart Harris | Cavendish |